|
|
| (120 dazwischenliegende Versionen von einem Benutzer werden nicht angezeigt) |
| Zeile 1: |
Zeile 1: |
| | __NOTOC__ | | __NOTOC__ |
| | *'''[[Further reading]]''' | | *'''[[Further reading]]''' |
| | + | |
| | | | |
| | *'''[[Unproven ideas]]''' | | *'''[[Unproven ideas]]''' |
| − | *'''[[Reviews on covid19 disease]]'''
| |
| | | | |
| | + | *'''[[Reviews on covid19 disease]]''' |
| | *'''[[Clinical guidelines and advice]]''' | | *'''[[Clinical guidelines and advice]]''' |
| | | | |
| − | ----
| |
| | | | |
| | | | |
| − | *'''[[Structure of covid19]]''' | + | *'''[[Respiration mgmt]]''' |
| − | {{tp|p=32361692|t=2020. How the COVID-19 Overcomes the Battle? An Approach to Virus Structure |pdf=|usr=}}
| + | |
| − | {{tp|p=32306836|t=2020. Novel 2019 coronavirus structure, mechanism of action, antiviral drug promises and rule out against its treatment |pdf=|usr=}}
| + | |
| | | | |
| − | *'''[[Target binding and uptake]]''' | + | *'''[[Diagnosis (Laboratory)]]''' |
| − | {{tp|p=32344526|t=2020. COVID-19 and RAS: Unravelling an Unclear Relationship |pdf=|usr=}}
| + | |
| − | {{tp|p=32274964|t=2020. A review on the cleavage priming of the spike protein on coronavirus by angiotensin-converting enzyme-2 and furin |pdf=|usr=}}
| + | |
| | | | |
| | | | |
| − | *'''[[Cytopathic effects]]''' | + | *'''[[Diagnosis (Lung CT, Sonography)]]''' |
| | | | |
| | + | *'''[[Diagnosis (other modalities)]]''' |
| | + | |
| | + | |
| | + | |
| | + | |
| | + | *'''[[Structure of covid19]]''' |
| | + | |
| | + | |
| | + | *'''[[Target binding and uptake]]''' |
| | + | *'''[[Cytopathic effects]]''' |
| | *'''[[Secretion and shedding]]''' | | *'''[[Secretion and shedding]]''' |
| | + | |
| | + | |
| | | | |
| | *'''[[Innate sensing]]''' | | *'''[[Innate sensing]]''' |
| | | | |
| | *'''[[Immunology]]''' | | *'''[[Immunology]]''' |
| − |
| |
| | | | |
| | *'''[[Cytokine storm, hemophagocytic lymphohistiocytosis, macrophage activation syndrome]]''' | | *'''[[Cytokine storm, hemophagocytic lymphohistiocytosis, macrophage activation syndrome]]''' |
| Zeile 32: |
Zeile 39: |
| | | | |
| | | | |
| − | ----
| + | *'''[[Pathobiology]]''' |
| | + | |
| | + | |
| | + | *'''[[Disease Models]]''' |
| | + | |
| | + | |
| | + | *'''[[Similar diseases and pathomechanisms]]''' |
| | + | |
| | + | |
| | | | |
| | | | |
| Zeile 41: |
Zeile 56: |
| | *'''[[Co-Infection]]''' | | *'''[[Co-Infection]]''' |
| | | | |
| − | *'''[[ARDS]]'''
| |
| | | | |
| | *'''[[Pulmonary embolism, coagulation]]''' | | *'''[[Pulmonary embolism, coagulation]]''' |
| − | {{tp|p=32311448|t=ä. COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-up |pdf=|usr=}}
| |
| | | | |
| − | *'''[[Hematology]]'''
| |
| | | | |
| − | *'''[[Microvascular]]'''
| |
| | | | |
| − | *'''[[Heart]]'''
| |
| | | | |
| − | *'''[[Neurology, ophthalmology, orl]]'''
| |
| − | *'''[[Dermatology]]'''
| |
| | | | |
| − | *'''[[Gastroenterology, hepatology]]''' | + | *'''[[Hematology]]''' |
| | | | |
| | | | |
| − | *'''[[Kidney, urology]]'''
| |
| | | | |
| − | ----
| + | *'''[[Heart]]''' |
| | | | |
| | | | |
| − | *'''[[Pathobiology]]'''
| |
| | | | |
| | + | *'''[[Neurology, ophthalmology, orl]]''' |
| | | | |
| | | | |
| − | *'''[[Disease Models]]'''
| |
| | | | |
| − | *'''[[Similar diseases and pathomechanisms]]''' | + | *'''[[Dermatology]]''' |
| − | ----
| + | |
| | | | |
| | | | |
| − | *'''[[Diagnosis (Laboratory)]]'''
| |
| − | *'''[[Diagnosis (Lung CT, Sonography)]]'''
| |
| | | | |
| − | *'''[[Diagnosis (other modalities)]]''' | + | *'''[[Gastroenterology, hepatology]]''' |
| − | {{tp|p=32344326|t=2020. COVID-19 and malaria: A symptom screening challenge for malaria endemic countries |pdf=|usr=}}
| + | |
| | | | |
| | + | *'''[[Kidney, urology]]''' |
| | | | |
| − | *'''[[Respiration mgmt]]''' | + | *'''[[The morbid survivor]]''' |
| − | {{tp|p=32339975|t=2020. Safe bronchodilator treatment in mechanically ventilated COVID-19 patients: A single center experience |pdf=|usr=}}
| + | |
| − | {{tp|p=32279018|t=ä. Poor survival with extracorporeal membrane oxygenation in acute respiratory distress syndrome (ARDS) due to coronavirus disease 2019 (COVID-19): Pooled analysis of early reports |pdf=|usr=}}
| + | |
| | | | |
| | + | *'''[[Risk and special populations]]''' |
| | | | |
| | | | |
| | | | |
| | + | *'''[[Case reports]]''' |
| | | | |
| − | *'''[[Risk and special populations]]'''
| |
| | | | |
| − | *'''[[The morbid survivor]]'''
| |
| − | {{tp|p=32334770|t=2020. The Need to Include Assisted Living in Responding to the COVID-19 Pandemic |pdf=|usr=}}
| |
| | | | |
| − | *'''[[Case reports]]'''
| |
| − | {{tp|p=32269194|t=2020. Pneumonia Without Respiratory Symptoms |pdf=|usr=}}
| |
| − | {{tp|p=32361703|t=2020. Newly Diagnosed Glomerulonephritis During COVID-19 Infection Undergoing Immunosuppression Therapy, a Case Report |pdf=|usr=}}
| |
| − | {{tp|p=32113824|t=ä. First case of Coronavirus Disease 2019 (COVID-19) pneumonia in Taiwan |pdf=|usr=}}
| |
| − | {{tp|p=32334915|t=ä. Letter to the Editor: Update on the followed-up CT exam of the first CoVID-19 pneumonia in Taiwan |pdf=|usr=}}
| |
| | | | |
| − | *'''[[Case series]]'''
| |
| | | | |
| | | | |
| − | *'''[[Registries]]'''
| |
| − | {{tp|p=32305438|t=ä. The AAD COVID-19 Registry: Crowdsourcing Dermatology in the Age of COVID-19 |pdf=|usr=}}
| |
| | | | |
| | + | *'''[[Case series]]''' |
| | | | |
| − | ----
| + | |
| | + | *'''[[Registries]]''' |
| | | | |
| | | | |
| | *'''[[Trials]]''' | | *'''[[Trials]]''' |
| − | {{tp|p=32290293|t=2020. A Review of SARS-CoV-2 and the Ongoing Clinical Trials |pdf=|usr=}}
| |
| − |
| |
| | | | |
| | *'''[[Candidate Compounds Covid19]]''' | | *'''[[Candidate Compounds Covid19]]''' |
| | | | |
| | | | |
| − | | + | *'''[[Other routes of infection]]''' |
| − | ----
| + | |
| | | | |
| | | | |
| | *'''[[Biophysics of aerosols]]''' | | *'''[[Biophysics of aerosols]]''' |
| − | {{tp|p=32340347|t=2020. Airborne Transmission Route of COVID-19: Why 2 Meters/6 Feet of Inter-Personal Distance Could Not Be Enough |pdf=|usr=}}
| |
| | | | |
| − | *'''[[Other routes of infection]]'''
| |
| − | {{tp|p=32335340|t=ä. Potential Fecal Transmission of SARS-CoV-2: Current Evidence and Implications for Public Health |pdf=|usr=}}
| |
| − | {{tp|p=32278800|t=ä. Sexual transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): A new possible route of infection?|pdf=|usr=}}
| |
| − | {{tp|p=32329026|t=ä. Study of SARS-CoV-2 in semen and urine samples of a volunteer with positive naso-pharyngeal swab |pdf=|usr=}}
| |
| | | | |
| | | | |
| − |
| |
| − | *'''[[Remission, recurrence and persistence]]'''
| |
| − | {{tp|p=32200109|t=2020. SARS-CoV-2 turned positive in a discharged patient with COVID-19 arouses concern regarding the present standard for discharge |pdf=|usr=}}
| |
| − | {{tp|p=32251796|t=ä. The enlightenment from two cases of asymptomatic infection with SARS-CoV-2: is it safe after 14 days of isolation?|pdf=|usr=}}
| |
| − | {{tp|p=32147538|t=2020. Recurrence of positive SARS-CoV-2 RNA in COVID-19: A case report |pdf=|usr=}}
| |
| − | {{tp|p=32340768|t=ä. Risk of reactivation or reinfection of novel coronavirus (COVID-19) |pdf=|usr=}}
| |
| | | | |
| | *'''[[Passive protective equipment]]''' | | *'''[[Passive protective equipment]]''' |
| | + | |
| | | | |
| | | | |
| | *'''[[Running your hospital]]''' | | *'''[[Running your hospital]]''' |
| − |
| |
| − | ----
| |
| | | | |
| | | | |
| | *'''[[Mental aspects of health professionals]]''' | | *'''[[Mental aspects of health professionals]]''' |
| − | {{tp|p=32259628|t=ä. Clinician Wellness During the COVID-19 Pandemic: Extraordinary Times and Unusual Challenges for the Allergist/Immunologist |pdf=|usr=}}
| |
| − | {{tp|p=32208139|t=ä. Coronavirus Disease 2019 (COVID-19) and Beyond: Micropractices for Burnout Prevention and Emotional Wellness |pdf=|usr=}}
| |
| | | | |
| | + | *'''[[Socio-psychiatric aspects of the status hygienicus]]''' |
| | | | |
| − |
| |
| − | *'''[[Socio-psychiatric aspects of the status hygienicus]]'''
| |
| | | | |
| | | | |
| | | | |
| | *'''[[Avoiding clinical medicine in other diseases]]''' | | *'''[[Avoiding clinical medicine in other diseases]]''' |
| − | {{tp|p=32283124|t=ä. Reduction in ST-Segment Elevation Cardiac Catheterization Laboratory Activations in the United States during COVID-19 Pandemic |pdf=|usr=}}
| + | |
| | | | |
| | | | |
| | *'''[[Occupational medicine, workplace security and status hygienicus]]''' | | *'''[[Occupational medicine, workplace security and status hygienicus]]''' |
| − |
| |
| − | *'''[[Economic aspects of the status hygienicus]]'''
| |
| − | {{tp|p=32325710|t=2020. The COVID-19 Outbreak and Affected Countries Stock Markets Response |pdf=|usr=}}
| |
| − | {{tp|p=32305533|t=ä. The Socio-Economic Implications of the Coronavirus and COVID-19 Pandemic: A Review |pdf=|usr=}}
| |
| − | {{tp|p=32292707|t=ä. Death and contagious infectious diseases: Impact of the COVID-19 virus on stock market returns |pdf=|usr=}}
| |
| | | | |
| | | | |
| | + | *'''[[Economic aspects of the status hygienicus]]''' |
| | | | |
| | | | |
| Zeile 180: |
Zeile 152: |
| | | | |
| | | | |
| − | *'''[[Failure of politics and public health guidance]]''' | + | |
| | + | |
| | + | *'''[[Remission, recurrence and persistence]]''' |
| | + | |
| | + | |
| | | | |
| | *'''[[Failure of executive measures]]''' | | *'''[[Failure of executive measures]]''' |
| | ---- | | ---- |
| | + | *'''[[Failure of politics and public health guidance]]''' |
| | | | |
| | | | |
| | *'''[[Political abuse of Covid19]]''' | | *'''[[Political abuse of Covid19]]''' |
| − | {{tp|p=32316647|t=2020. Using Social Media to Mine and Analyze Public Opinion Related to COVID-19 in China |pdf=|usr=}}
| + | |
| − | *[https://www.businessinsider.com/nearly-half-of-reopen-america-twitter-accounts-are-bots-report-2020-5?utmSource=twitter&utmContent=referral&utmTerm=topbar&referrer=twitter twitter botwar]
| + | |
| | | | |
| | | | |
| | *'''[[Lost people]]''' | | *'''[[Lost people]]''' |
| − | {{tp|p=32142979|t=2020. Li Wenliang, a face to the frontline healthcare worker The first doctor to notify the emergence of the SARS-CoV-2, (COVID-19), outbreak |pdf=|usr=}}
| |
| − | {{tp|p=32271208|t=ä. Survey of COVID-19 Disease Among Orthopaedic Surgeons in Wuhan, People?s Republic of China |pdf=|usr=}}
| |
| − |
| |
| | | | |
| | *'''[[Lost civilization]]''' | | *'''[[Lost civilization]]''' |
| | + | |
| | ---- | | ---- |
| | | | |
| | | | |
| | *'''[[History of covid19 exploration]]''' | | *'''[[History of covid19 exploration]]''' |
| − | {{tp|p=32120913|t=2020. Epidemiological Identification of A Novel Pathogen in Real Time: Analysis of the Atypical Pneumonia Outbreak in Wuhan, China, 2019?2020 |pdf=|usr=}}
| |
| − |
| |
| | *'''[[misc.]]''' | | *'''[[misc.]]''' |
| | + | |
| | + | |
| | *'''[[Research tools]]''' | | *'''[[Research tools]]''' |
| | + | |
| | + | |
| | + | |
| | + | |
| | + | {{tp|p=27490990|t=2017. AVCpred: an integrated web server for prediction and design of antiviral compounds |pdf=|usr=}} |
| | + | {{tp|p=25040500|t=2014. Engineering large viral DNA genomes using the CRISPR?Cas9 system |pdf=|usr=}} |
| | + | |
| | + | |
| | + | *'''[[PrePrint scene]]''' |
| | + | |
| | | | |
| | *'''[[from the ads]]''' | | *'''[[from the ads]]''' |
| − | *[lifechemicals.com antiviral candidate drugs]
| |
| − | *[biomol.com assays cytokines general spectrum]
| |
| − | *[labospace.com custom single probe assay 400 possible cytokines and so on]
| |
| − | *
| |
| | | | |
| | *'''[[Current state of coviki.org]]''' | | *'''[[Current state of coviki.org]]''' |
| | + | *'''[[on-topic personal thoughts]]''' |
